A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs

Area of Science:

• Oncology
• Pharmacology
• Veterinary Medicine

Background:

• Paclitaxel is a widely used chemotherapeutic agent derived from the Pacific yew tree, known for its efficacy against various human cancers.
• It functions as a taxane, inhibiting microtubule dynamics, which disrupts mitosis and induces apoptosis in cancer cells.
• Beyond microtubule inhibition, paclitaxel exhibits anticancer effects through cell proliferation suppression and antiangiogenic properties.

Purpose of the Study:

• To review the evidence supporting paclitaxel's broad anticancer activity in humans.
• To introduce novel paclitaxel formulations designed for targeted cancer delivery and reduced hypersensitivity.
• To highlight recent advancements in paclitaxel formulations, particularly for veterinary applications.

Main Methods:

• Literature review of paclitaxel's mechanism of action and clinical applications.
• Summary of research on novel paclitaxel formulations and their development.
• Analysis of data regarding the efficacy and safety of new formulations, including veterinary studies.

Main Results:

• Paclitaxel demonstrates significant efficacy across a wide range of human cancers due to its targeting of the mitotic complex.
• New formulations are being developed to enhance tumor targeting and mitigate adverse effects like hypersensitivity.
• A novel nanoparticle paclitaxel formulation has received conditional FDA approval for specific canine cancers, showing reduced hypersensitivity.

Conclusions:

• Paclitaxel remains a crucial chemotherapeutic agent with diverse anticancer mechanisms.
• Ongoing research into novel formulations promises improved therapeutic outcomes and safety profiles.
• The development of targeted nanoparticle formulations represents a significant advancement, particularly with recent veterinary approvals.